American Cryostem

American Cryostem FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of American Cryostem (CRYO) as of Nov 11, 2026 is 12.04 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 44.72 % — a change of -73.09% (lower).

FCF Conversion

12.04 %

YoY

-73.09%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of American Cryostem is 2021 12.04 % . FCF Conversion Rate (FCF/EBITDA) of American Cryostem was 2020 44.72 % . It decreases by -73.09% lower compared to the previous year.

The American Cryostem FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
41.15 USD
Jan 1, 2015
33.50 USD
Jan 1, 2016
29.34 USD
Jan 1, 2017
-21.28 USD
Jan 1, 2018
26.80 USD
Jan 1, 2019
50.54 USD
Jan 1, 2020
44.72 USD
Jan 1, 2021
12.04 USD
The American Cryostem FCF Conversion history
YEARFCF ConversionYoY
12.04 %-73.09%
44.72 %-11.51%
50.54 %+88.55%
26.80 %-225.97%
-21.28 %-172.52%
29.34 %-12.43%
33.50 %-18.58%
41.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Cryostem Stock analysis

What does American Cryostem do? American Cryostem Corporation (ACC) is a biotechnology company based in New Jersey that specializes in the development of stem cell products. The company was founded in 2008 and went public in the same year. ACC utilizes cutting-edge technologies to isolate, expand, store, and transport human stem cells. The company offers a wide range of stem cell products and services, with applications in regenerative medicine, cosmetics, sports medicine, and biomedical research. ACC collaborates with academic research institutions, biomedical companies, and clinical facilities to enable innovations in stem cell research. The company has a close partnership with Rutgers University in New Jersey, one of the leading research institutions in the field of stem cell research. The products and services of American Cryostem Corp include a variety of stem cell products and services, such as isolation of stem cells from adipose tissue, expansion of stem cells, cryopreservation of stem cells, and tissue and organ regeneration. The business model of American Cryostem Corp is based on the utilization of stem cells derived from human adipose tissue. The company uses advanced technologies to isolate, expand, store, and transport these stem cells. The stem cell products can be used in medicine, cosmetics, and biomedical research. One of the key areas of American Cryostem Corp is regenerative medicine. The company develops stem cell therapies for the treatment of various diseases and injuries. American Cryostem Corp has a range of stem cell products that can be used for tissue and organ regeneration. Another focus of American Cryostem Corp is the cosmetics industry. The company offers a wide range of stem cell products for improving skin health and beauty. These products can be used for skin rejuvenation, reducing wrinkles, and improving skin texture. American Cryostem Corp is also active in sports medicine. The company offers stem cell products that can be used in the treatment of sports injuries. These products can be used for the regeneration of muscles, tendons, and ligaments. The company is also involved in biomedical research. American Cryostem Corp offers stem cell products and services that can be utilized by academic institutions and biomedical companies for developing new therapies and medications. American Cryostem Corp has a strong innovation capacity and continuously invests in research and development. The company has filed several patents for its technologies and products and is working on the development of new therapies and stem cell products. Overall, American Cryostem Corp is a leading biotechnology company specializing in the development of stem cell products and services. The company has a wide range of products with diverse applications in medicine, cosmetics, sports medicine, and biomedical research. American Cryostem Corp has a strong innovation capacity and aims to develop new therapies and stem cell products that can improve people's well-being. American Cryostem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Cryostem stock

FCF Conversion Rate (FCF/EBITDA) of American Cryostem is 12.04 % in 2021.

FCF Conversion Rate (FCF/EBITDA) of American Cryostem changed from 44.72 % to 12.04 %, representing a -73.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) American Cryostem since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s American Cryostem with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — American Cryostem

All Key Metrics — American Cryostem